MENLO PARK, Calif.--()--IncellDx scientists presented data using IncellDx’s proprietary OncoBreast 3Dx™ technology to multiplex protein markers for tumor type (E-cadherin) and ER status, markers for her-2 neu protein and mRNA as well as DNA cell cycle and ploidy, all in intact tumor cells in suspension. The study, presented at the 25th Annual CSU Biotechnology Symposium by Amanda Chargin and co-authored by Keith Shults, demonstrated the feasibility of multiplexing proteins, mRNA and DNA cell cycle using flow cytometry on breast cancer cells obtained by fine needle aspiration.
“Multiplex assays are not just genes or just proteins anymore but can be proteins, RNA, DNA and morphology in our 3Dx platform”
“The development of OncoBreast 3Dx™ demonstrates the breadth of IncellDx’s 3Dx technology to future diagnostic applications in women’s health”, said IncellDx CEO Bruce K. Patterson MD. “Multiplex assays are not just genes or just proteins anymore but can be proteins, RNA, DNA and morphology in our 3Dx platform,” he added.
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.